Vitamin D as therapeutic modulator in cerebrovascular diseases: a mechanistic perspectives

Vivek Rihal1, Heena Khan1, Amarjot Kaur1

  • 1Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India.

Insights

Vitamin D deficiency is linked to chronic diseases and cardiovascular issues. Supplementation may help manage cerebrovascular disorders like stroke by modulating key molecular pathways.

Area of Science:

  • Endocrinology and Metabolism
  • Cardiovascular Science
  • Neuroscience

Background:

  • Vitamin D deficiency is associated with major chronic diseases, including cardiovascular and neurodegenerative disorders.
  • Deficiency particularly impacts cardiovascular health, leading to endothelial dysfunction and vascular abnormalities.
  • These effects are linked to oxidative stress, inflammation, and aging processes.

Approach:

  • This review examines therapeutic strategies targeting vitamin D inadequacy and its downstream effects.
  • Focuses on how vitamin D modulates molecular pathways crucial in cerebrovascular health.
  • Analyzes vitamin D's role in mitigating impaired autophagy and inflammatory/oxidant reactions.

Key Points:

  • Vitamin D influences critical molecular pathways such as Nitric Oxide, PI3K-Akt, cAMP, NF-kB, Sirtuin 1, Nrf2, and FOXO.
  • Evidence suggests vitamin D can slow the progression of cerebrovascular disorders.
  • Therapeutic approaches targeting vitamin D may reduce the severity of stroke and neurologic malformations.

Conclusions:

  • Vitamin D plays a significant role in preventing and managing cerebrovascular disorders.
  • Addressing vitamin D deficiency offers a potential strategy to combat stroke and related neurological conditions.
  • Further research into vitamin D's therapeutic applications is warranted for global health improvement.

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.4K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
486
Pharmacodynamics: Overview and Principles01:21

Pharmacodynamics: Overview and Principles

Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
2.3K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
219
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
278
Connective Tissue Cell Types01:22

Connective Tissue Cell Types

Connective tissue develops from the mesoderm of a developing embryo and consists of cells, fibers, and ground substance: a gel-like material containing large complexes of carbohydrates and proteins. Connective tissue was first identified as a separate tissue family in the 18th century, and Johannes Peter Muller coined the term connective tissue.
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
3.5K